# reload+after+2024-01-21 22:45:32.093570
address1§430 East 29th Street
city§New York
state§NY
zip§10016
country§United States
phone§646 440 9333
website§https://www.intracellulartherapies.com
industry§Drug Manufacturers—Specialty & Generic
sector§Healthcare
longBusinessSummary§Intra-Cellular Therapies, Inc., a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States. The company offers CAPLYTA for the treatment of schizophrenia and bipolar depression in adults. It is also involved in developing Lumateperone, which is in Phase 3 clinical trial for the treatment of various depressive disorders, as well as additional neuropsychiatric indications. In addition, the company is developing Lenrispodun (ITI-214) for the treatment of Parkinson's disease, heart failure, CNS, and other disorders; ITI-1284 for the treatment of neuropsychiatric disorders and behavioral disturbances in dementia; and ITI-333 for substance use disorders, pain, and psychiatric comorbidities, including depression, anxiety, and sleep disorders. Intra-Cellular Therapies, Inc. was founded in 2002 and is headquartered in New York, New York.
fullTimeEmployees§561
companyOfficers§[{'maxAge': 1, 'name': 'Dr. Sharon  Mates Ph.D.', 'age': 70, 'title': 'Co-Founder, Chairman, CEO & President', 'yearBorn': 1953, 'fiscalYear': 2022, 'totalPay': 2232869, 'exercisedValue': 1989068, 'unexercisedValue': 36508148}, {'maxAge': 1, 'name': 'Mr. Lawrence J. Hineline CPA', 'age': 67, 'title': 'Senior VP of Finance, CFO, Treasurer & Assistant Secretary', 'yearBorn': 1956, 'fiscalYear': 2022, 'totalPay': 820533, 'exercisedValue': 2357977, 'unexercisedValue': 2747821}, {'maxAge': 1, 'name': 'Mr. Michael I. Halstead J.D.', 'age': 50, 'title': 'Executive VP, General Counsel & Secretary', 'yearBorn': 1973, 'fiscalYear': 2022, 'totalPay': 983651, 'exercisedValue': 1912995, 'unexercisedValue': 4438195}, {'maxAge': 1, 'name': 'Dr. Suresh K. Durgam M.D.', 'age': 54, 'title': 'Executive VP & Chief Medical Officer', 'yearBorn': 1969, 'fiscalYear': 2022, 'totalPay': 961836, 'exercisedValue': 0, 'unexercisedValue': 4973458}, {'maxAge': 1, 'name': 'Mr. Mark  Neumann', 'age': 60, 'title': 'EVP & Chief Commercial Officer', 'yearBorn': 1963, 'fiscalYear': 2022, 'totalPay': 998358, 'exercisedValue': 4459011, 'unexercisedValue': 2515331}, {'maxAge': 1, 'name': 'Dr. Robert E. Davis Ph.D.', 'age': 72, 'title': 'Senior VP & Chief Scientific Officer', 'yearBorn': 1951, 'fiscalYear': 2022, 'totalPay': 646124, 'exercisedValue': 0, 'unexercisedValue': 169900}, {'maxAge': 1, 'name': 'Mr. Juan Fernando Sanchez', 'age': 52, 'title': 'Vice President of Corporate Communications & Investor Relations', 'yearBorn': 1971, 'fiscalYear': 2022, 'totalPay': 296753, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Ms. Karen Patruno Sheehy Esq.', 'age': 61, 'title': 'Senior VP & Chief Compliance Officer', 'yearBorn': 1962, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Michael  Olchaskey', 'title': 'Senior VP & Head of Regulatory Affairs', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. John A. Bardi', 'title': 'Senior VP of Market Access, Policy & Government Affairs', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}]
auditRisk§8
boardRisk§7
compensationRisk§6
shareHolderRightsRisk§7
overallRisk§7
governanceEpochDate§1704067200
compensationAsOfEpochDate§1672444800
maxAge§86400
priceHint§2
payoutRatio§0.0
beta§1.013
priceToSalesTrailing12Months§15.690745
currency§USD
dateShortInterest§1702598400
forwardEps§-0.54
pegRatio§-0.44
exchange§NMS
quoteType§EQUITY
shortName§Intra-Cellular Therapies Inc.
longName§Intra-Cellular Therapies, Inc.
firstTradeDateEpochUtc§1389105000
timeZoneFullName§America/New_York
timeZoneShortName§EST
uuid§663c5e9c-25b0-3a49-b384-beebac54b1ca
gmtOffSetMilliseconds§-18000000
targetHighPrice§101.0
targetLowPrice§58.0
targetMeanPrice§78.47
targetMedianPrice§76.29
recommendationMean§1.9
recommendationKey§buy
numberOfAnalystOpinions§16
quickRatio§5.778
grossMargins§0.54048
ebitdaMargins§-0.40977
trailingPegRatio§None
